Tim Miller, Forge Biologics CEO

CNS-fo­cused gene ther­a­py biotech forges man­u­fac­tur­ing deal for hear­ing loss drug

A grow­ing gene ther­a­py com­pa­ny is team­ing up with one of the largest gene ther­a­py man­u­fac­tur­ers to get its drug in­to pa­tients in clin­i­cal tri­als.

Myrtelle an­nounced on Mon­day that it inked a deal with Forge Bi­o­log­ics to make Myr-201, a gene ther­a­py in­di­cat­ed for mono­genic hear­ing loss. The tar­get pa­tient pop­u­la­tion, Myrtelle said, is peo­ple with a type of hear­ing loss called DFNB8, or au­to­so­mal re­ces­sive deaf­ness 8.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.